TCR2 Therapeutics Inc. TCRR
At closeMay 31, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 58.11M
- Shares out
- 39.26M
- Forward P/E
- -0.60
- Volume
- 3.75M
- Open
- 1.58
- Previous close
- 1.48
- Day's range
- 1.48 – 1.48
- Beta
- 1.93
- Analysts
- Hold
- Price target
- 6.43 (+334.5%)
- Earnings date
- May 11, 2023
2Y -5.50 (-78.80%)
Key statistics
- Enterprise value
- -46.22M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -69.13M
- Total cash
- 110.31M
- Total debt
- 5.98M
- Return on equity
- -91.46%
- Short % of float
- 1.16%
- 50-day average
- 1.69
- 200-day average
- 1.56
Analyst view
Consensus: hold
- Target (low)
- 1.72
- Target (mean)
- 6.43
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold7
- Sell0
- Strong sell0
Next earnings
May 11, 2023
Expected May 11, 2023. Consensus EPS estimate -0.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 11, 2023 | Mar 1, 2023 | -0.76 | — | — | — |
| Mar 23, 2023 | Dec 1, 2022 | -0.80 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -0.83 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.77 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.74 | — | — | — |
| Mar 22, 2022 | Dec 1, 2021 | -0.75 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 24, 2023 | Mizuho | down | Buy | Neutral |
| Mar 23, 2023 | EF Hutton | reit | — | Hold |
| Mar 9, 2023 | Jefferies | down | Buy | Underperform |
| Mar 8, 2023 | Truist Securities | down | Buy | Hold |
| Mar 7, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 6, 2023 | Piper Sandler | main | — | Overweight |
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tcr2.com
News
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 
5 Penny Stocks To Buy According To Analysts, Targets Up To 952% 
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? 
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path 
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023 
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
- Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on TCRR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARDAMA ALFONSO QUINTAS | Officer | Sale | Dec 12, 2022 | 109,459 |
| GADICKE ANSBERT S. | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | May 21, 2023 | 0 |
| GIBSON NEIL W | Director | Sale | Mar 19, 2020 | 0 |
| HOFMEISTER ROBERT PH.D. | Officer | Conversion of Exercise of derivative security | Dec 21, 2020 | 45,850 |
| JUSTICE ANGELA | Officer | Sale | Dec 11, 2022 | 48,745 |
| MENZEL GARRY E | Chief Executive Officer | Sale | Dec 12, 2022 | 575,139 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Asset Management, LLC | 10.32% | 4,050,865 | 6.00M | Mar 30, 2023 |
| Tang Capital Management, LLC | 8.66% | 3,399,745 | 5.03M | Mar 30, 2023 |
| BioImpact Capital LLC | 8.59% | 3,370,982 | 4.99M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.74% | 1,468,802 | 2.17M | Mar 30, 2023 |
| Newtyn Management, Llc | 2.59% | 1,015,920 | 1.50M | Mar 30, 2023 |
| Acadian Asset Management. LLC | 2.07% | 812,459 | 1.20M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 981,016 | 1.45M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.12% | 439,478 | 650.43K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.47% | 185,778 | 274.95K | Feb 27, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.38% | 148,400 | 219.63K | Dec 30, 2022 |
| iShares US Small-Cap Equity Factor ETF | 0.31% | 120,862 | 178.88K | Feb 27, 2023 |
| Collaborative Inv Ser Tr-Greenwich Ivy Long-Short Fd | 0.18% | 71,616 | 105.99K | Dec 30, 2022 |